Sandoz

News

Sandoz says it is entering "golden decade" in biosimilars

Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.

News

Sandoz adds 10 biosimilars through $322m Henlius deal

Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.

News

Sandoz will pay another $480m to settle US antitrust suits

Sandoz has reached a settlement in the US that, if approved, could lay to rest years of litigation over price-fixing of generic medicines.

News

Trump sets course for 100%, then 200%, tariffs on generics

Trump has said he intends to impose tariffs of 100% on generic drugs imported into the US from 2028, rising to 200% after a year, in a reshoring push.

Patients

pharmaphorum podcast Episode 263, Rebecca Guntern - Sandoz

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

News

A pregnant woman with her hands forming a heart shape over her bump, wearing a beige sweater

NICE recommends wider use of MS drug natalizumab via NHS

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

Sandoz says it is entering "golden decade" in biosimilars

Sandoz adds 10 biosimilars through $322m Henlius deal

Sandoz will pay another $480m to settle US antitrust suits

Trump sets course for 100%, then 200%, tariffs on generics

Biosimilars & patient access independent of geographies or s...

NICE recommends wider use of MS drug natalizumab via NHS

CHMP backs Novo's haemophilia A drug Frehemgo

Discover a new era of healthcare panel engagement: Grounded ...

Sandoz

Editor's Picks